ViGeneron Rebrands, Gets FDA Rare Pediatric Disease Designation

Rare Daily Staff

ViGeneron has changed its name to VeonGen Therapeutics, a rebranding intended to reflect its evolution into a clinical-stage genetic medicine company focused on developing gene therapies for patients with high unmet medical needs.

With the name change, VeonGen announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to the company’s lead program, VG801, to treat ABCA4 mutation-associated retinal dystrophy.

The FDA grants a Rare Pediatric Disease designation when preclinical data for an experimental drug or therapy suggest the treatment could effectively treat a rare disease primarily affecting children. The designation can enable the award of a Priority Review Voucher (PRV) if a gene therapy is approved, should Congress move to renew the PRV program. The program expired, but legislation has been introduced to extend it.” to avoid repetition. A company that receives approval for a drug for a rare pediatric disease can use the PRV to speed the FDA review process for another product. The voucher is potentially lucrative because it is transferable. Recently, companies have sold their vouchers to other drug developers for around $150 million each.

VG801 is currently being evaluated in a first-in-human phase 1/2 clinical trial, with patient dosing underway. VeonGen is developing a functional endpoint in collaboration with the FDA through the Rare Disease Endpoint Advancement (RDEA) pilot program. VG801 aims to treat patients with biallelic ABCA4 mutations linked to Stargardt disease and related retinal dystrophies, the most common inherited retinal disease and a leading cause of macular degeneration in children and young adults.

The company has advanced two first-in-class gene therapy programs into clinical development. In addition to VG801, it is developing VG901, an intravitreally delivered AAV gene therapy for retinitis pigmentosa caused by CNGA1 mutations. Both programs use VeonGen’s proprietary genetic medicine platforms, designed to address critical gene delivery challenges in AAV-based therapies. The technology utilizes mRNA trans-splicing to deliver large genes exceeding the AAV cargo limits. Its technology, known as vgAAV, is an engineered capsid platform optimized for safe and efficient delivery via intravitreal or subretinal administration.

“This rebranding reflects our journey—from a platform innovator to a clinical-stage company with two gene therapies in the clinic. With VG801 and VG901 progressing in clinical trials and our platforms demonstrating robust translational potential, we are well positioned to expand the frontier of genetic medicine in ophthalmology and beyond,” said Caroline Man Xu, co-founder and CEO of VeonGen Therapeutics. “The FDA Rare Pediatric Disease Designation for VG801 not only highlights the strength of our scientific approach but also reinforces our focus on accelerating the development and delivery of transformative therapies for patients in urgent need.”

VeonGen’s proprietary gene therapy platforms are designed for broad therapeutic applicability. In addition to ophthalmology, the company is exploring expansion and partnerships in cardiovascular, central nervous system (CNS), and other disease areas.